RFS Pharma, LLC
Records under this name other than patents RFS Pharma, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,415,321 | Nucleoside Derivatives for Treatment of Caliciviridae Infections, Including Norovirus Infections Formerly held In force · High confidence | In force | High confidence | |
| US 9,181,227 | Potent and Selective Inhibitors of Hepatitis C Virus Formerly held In force · High confidence | In force | High confidence | |
| US 9,809,616 | Pyrimidine Nucleosides and Their Monophosphate Prodrugs for Treatment of Viral Infections and Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 8,815,829 | 3'-Azido Purine Nucleotide Prodrugs for Treatment of Viral Infections Formerly held Lapsed on the fee record Ended Aug 26, 2026 · High confidence | Lapsed on the fee record | Ended Aug 26, 2026 | High confidence |
| US 8,895,531 | 2′-fluoronucleoside phosphonates as antiviral agents Formerly held Lapsed on the fee record Ended Nov 25, 2022 · From the USPTO record | Lapsed on the fee record | Ended Nov 25, 2022 | From the USPTO record |
| US 8,859,595 | Potent and Selective Inhibitors of Hepatitis C Virus Formerly held Lapsed on the fee record Ended Oct 14, 2022 · High confidence | Lapsed on the fee record | Ended Oct 14, 2022 | High confidence |
| US 8,609,627 | Purine Nucleoside Monophosphate Prodrugs for Treatment of Cancer and Viral Infections Formerly held Lapsed on the fee record Ended Dec 17, 2021 · High confidence | Lapsed on the fee record | Ended Dec 17, 2021 | High confidence |
| US 9,173,893 | Purine Nucleoside Monophosphate Prodrugs for Treatment of Cancer and Viral Infections Formerly held Lapsed on the fee record Ended Nov 3, 2019 · High confidence | Lapsed on the fee record | Ended Nov 3, 2019 | High confidence |
| US 9,040,479 | HCV NS3 protease inhibitors Formerly held Lapsed on the fee record Ended May 26, 2019 · From the USPTO record | Lapsed on the fee record | Ended May 26, 2019 | From the USPTO record |
| US 8,729,014 | Specific HCV NS3 protease inhibitors Formerly held Lapsed on the fee record Ended May 20, 2018 · From the USPTO record | Lapsed on the fee record | Ended May 20, 2018 | From the USPTO record |